HR-positive/HER2-negative breast cancer grows with estrogen or progesterone, lacking high HER2 protein levels, making hormone ...
Stephen Johnston, Ph.D., from the Royal Marsden NHS Foundation Trust in London, and colleagues reported the primary OS results for patients with HR-positive, HER2-negative, node-positive, high-risk ...
You have a critical role in determining your breast cancer treatment plan. Here’s how you can work with your doctor. According to the National Cancer Institute ...
Dr. Beverly Moy is back on the ASCO Guidelines Podcast to discuss the latest guideline rapid recommendation update regarding sacituzumab govitecan for patients with hormone receptor-positive ...
Imlunestrant is approved for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, showing improved progression-free survival with abemaciclib. The oral administration of ...
The FDA expanded the approval of trastuzumab deruxtecan (T-DXd, Enhertu) to include treatment of unresectable/metastatic hormone receptor (HR)-positive, HER2-low ...
A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast ...
Verywell Health on MSN
Triple-Negative Breast Cancer Recurrence After Mastectomy
Medically reviewed by Archana Sharma, DO Key Takeaways Even after surgery, triple-negative breast cancer has a high chance of ...
No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2007 ASCO Annual Meeting. This abstract does not include a full text component.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback